Breast Cancer

Emiel J. Rutgers, MD, surgical oncologist, Netherlands Cancer Institute, Amsterdam, discusses a study analyzing radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, describes the potential impact of the cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in the treatment of patients with ER-positive metastatic breast cancer.

Women with early sentinel lymph node-positive breast cancer achieve as much of a disease-free and survival benefit from axillary radiotherapy as they do from axillary lymph node dissection with significantly less risk of lymphedema.

Jane E. Churpek, MD, discusses a study that found the inherited mutations in breast cancer genes in African American breast cancer patients were revealed by targeted genomic capture and next-generation sequencing.

New research suggests that HER2-targeted drugs may actually have much broader applications, benefiting patients who are not designated HER2-positive by routine testing.

Low-dose weekly paclitaxel is as effective and has fewer side effects than the standard biweekly schedule for patients with early-stage breast cancer.

Clifford A. Hudis, MD, ASCO President-Elect, describes the focus on global medicine at the 2013 American Society of Clinical Oncology Annual Meeting.

A British study has confirmed that 10 years of adjuvant tamoxifen substantially reduces late breast cancer recurrence and mortality among women with estrogen receptor-positive disease.